Table 1

Demographic, clinical and MRI characteristics of the studied population during different treatment periods

TreatmentPre-NTZNTZDMF
Female27 (69.2%)
Age at MS onset (years)*28.8±8.1
Age at study entry (years)*34.8±8.6
Treatment duration (months)*32.3±7.128.3±5.324.0±4.5
EDSS at baseline†1.5 (1.0–2.5)2.0 (1.0–3.5)2.0 (1.0–3.5)
Patients with relapse39 (100%)3 (7.7%)5 (12.8%)
EDSS change†0.5 (0–1)0 (0–1)0 (0–1.5)
MRI activity‡39 (100%)6 (15.4%)8 (20.5%)
Disability progression§23 (58.9%)1 (2.6%)3 (7.7%)
NEDA-3033 (84.6%)31 (79.5%)
  • *Data are expressed as mean ±SD.

  • †Data are expressed as median (range).

  • ‡New or enlarged lesions in T2-derived sequences (including DIR) or T1-Gd+lesions.

  • §Confirmed at 6 months.

  • DIR, double inversion recovery; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; NEDA, no evidence of disease activity; NTZ, natalizumab; DMF, dimetilfumarate.